FDA expands nogapendekin alfa inbakicept plus BCG use to high-grade papillary-only BCG-unresponsive NMIBC, offering durable control and strong cystectomy-avoidance outcomes.
Commentary|Articles|September 25, 2025
Oncologists Choose Top Goals and Therapies for Treating MDS
Author(s)Luke Fletcher, MD
Fact checked by: Dylann Bailey
Luke Fletcher, MD, reviews updates in anemia-predominant MDS and the 2025 polling results from MDS Case-Based Roundtable events.
Advertisement
Advertisement
Myelodysplastic syndrome (MDS) is a heterogeneous clonal hematologic neoplasm defined by cytopenias, dysplasia, and clonal cytogenetic and molecular abnormalities.1 The heterogeneity is evident in that prognosis can range from months to over 10 years, depending on the features of the MDS. Therefore, making the diagnosis and risk stratification as precise as possible is imperative in the selection of treatment.
Related to this article
Real-world German MINT data show mogamulizumab delivers durable responses, ~20-month PFS, manageable safety, and improved quality of life in MF and Sézary syndrome.
The phase 2 PEGASUS trial of ctDNA-guided adjuvant therapy in high-risk stage II/III colon cancer missed its primary end point but reduced neurotoxicity.
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies—yet gaps persist, and research funding uncertainty threatens future gains.
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
This marks the fourth submission to the FDA for approval of rivoceranib plus camrelizumab for this first-line indication in hepatocellular carcinoma.
The FDA granted FTD to opantistomig, a PD-L1/4-1BB bispecific antibody, for first-line treatment of biliary tract cancer.
Texas Oncology’s virtual care navigation pilot supported 740 patients on oral oncolytics across 11 community sites, offering a scalable model for at-home care.
Advertisement
Advertisement